BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24549759)

  • 1. Subependymal giant cell astrocytoma: current concepts, management, and future directions.
    Ouyang T; Zhang N; Benjamin T; Wang L; Jiao J; Zhao Y; Chen J
    Childs Nerv Syst; 2014 Apr; 30(4):561-70. PubMed ID: 24549759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of subependymal giant cell astrocytoma.
    Beaumont TL; Limbrick DD; Smyth MD
    Childs Nerv Syst; 2012 Jul; 28(7):963-8. PubMed ID: 22562196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
    Ichikawa T; Niida Y
    No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytomas Treated with Laser Interstitial Thermal Therapy, Open Surgical Resection, and mTOR Inhibitors.
    Boop S; Bonda D; Randle S; Leary S; Vitanza N; Crotty E; Novotny E; Friedman S; Ellenbogen RG; Durfy S; Goldstein H; Ojemann JG; Hauptman JS
    Pediatr Neurosurg; 2023; 58(3):150-159. PubMed ID: 37232001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
    Jiang T; Du J; Raynald ; Wang J; Li C
    World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
    J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
    Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
    Jóźwiak S; Nabbout R; Curatolo P;
    Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
    Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
    Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
    Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
    BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated subependymal giant cell astrocytoma (SEGA) in the absence of clinical tuberous sclerosis: two case reports and literature review.
    Cobourn KD; Chesney KM; Mueller K; Fayed I; Tsering D; Keating RF
    Childs Nerv Syst; 2024 Jan; 40(1):73-78. PubMed ID: 37658938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.
    Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J
    Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic endoscopic resection and surgical management of a subependymal giant cell astrocytoma: case report.
    Rodgers SD; Bassani L; Weiner HL; Harter DH
    J Neurosurg Pediatr; 2012 Apr; 9(4):417-20. PubMed ID: 22462708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.
    Yalon M; Ben-Sira L; Constantini S; Toren A
    Childs Nerv Syst; 2011 Jan; 27(1):179-81. PubMed ID: 20703486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.